Evidence map›Paper›PMID 36118880›Full record

ReviewFrontiers in genetics2022

MicroRNA-mediated regulation of key signaling pathways in hepatocellular carcinoma: A mechanistic insight.

Luis M Ruiz-Manriquez, Oscar Carrasco-Morales, E Adrian Sanchez Z, Sofía Madeline Osorio-Perez, Carolina Estrada-Meza, Surajit Pathak, Antara Banerjee, Anindya Bandyopadhyay, Asim K Duttaroy, Sujay Paul

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Frontiers in pharmacology · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Luis M Ruiz-ManriquezTecnologico de Monterrey, School of Engineering and Sciences, Queretaro, Mexico.
Oscar Carrasco-MoralesTecnologico de Monterrey, School of Engineering and Sciences, Queretaro, Mexico.
E Adrian Sanchez ZTecnologico de Monterrey, School of Engineering and Sciences, Queretaro, Mexico.
Sofía Madeline Osorio-PerezTecnologico de Monterrey, School of Engineering and Sciences, Queretaro, Mexico.
Carolina Estrada-MezaTecnologico de Monterrey, School of Engineering and Sciences, Queretaro, Mexico.
Surajit PathakDepartment of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India.
Antara BanerjeeDepartment of Medical Biotechnology, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India.
Anindya BandyopadhyayInternational Rice Research Institute, Manila, Philippines.
Asim K DuttaroyDepartment of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
Sujay PaulTecnologico de Monterrey, School of Engineering and Sciences, Queretaro, Mexico.
Tecnológico de Monterrey · MXChettinad Academy of Research and Education · INInternational Rice Research Institute · PHUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. The molecular pathogenesis of HCC varies due to the different etiologies and genotoxic insults. The development of HCC is characterized by complex interactions between several etiological factors that result in genetic and epigenetic changes in proto-onco and/or tumor suppressor genes. MicroRNAs (miRNAs) are short non-coding RNAs that also can act as oncomiRs or tumor suppressors regulating the expression of cancer-associated genes post-transcriptionally. Studies revealed that several microRNAs are directly or indirectly involved in cellular signaling, and dysregulation of those miRNAs in the body fluids or tissues potentially affects key signaling pathways resulting in carcinogenesis. Therefore, in this mini-review, we discussed recent progress in microRNA-mediated regulation of crucial signaling networks during HCC development, concentrating on the most relevant ones such as PI3K/Akt/mTOR, Hippo-YAP/TAZ, and Wnt/β-catenin, which might open new avenues in HCC management.

Indexed as

gene regulationhepatocellular carcinomamiRNAsignaling pathwaystherapeutics

Identifiers

PMID36118880
PMCPMC9478853
OpenAlexW4294225748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.